Abstract:Despite recent clinical progress in peptide-based dual inhibitors of MDM2/4, small-molecule ones with robust antitumor activities remain challenging. To tackle this issue, 31 (YL93) was structure-based designed and synthesized, which had MDM2/4 binding Ki values of 1.1 and 642 nM, respectively. In three MDM4-overexpressing cancer cell lines harboring wild-type p53, 31 shows improved cell growth inhibition activities compared to RG7388, an MDM2-selective inhibitor in late-stage clinical trials. Mechanistic studies show that 31 increased cellular protein levels of p53 and p21 and upregulated the expression of p53-targeted genes in RKO cells with MDM4 amplification. In addition, 31 induced cell-cycle arrest and apoptosis in western blot and flow cytometry assays. Taken together, dual inhibition of MDM2/4 by 31 elicited stronger antitumor activities in vitro compared to selective MDM2 inhibitors in wild-type p53 and MDM4-overexpressing cancer cells.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00095.qPCR analysis of TP53 and MDM4 genes in RKO cells in the presence of YL93 for 24 h (Figure S1); flow cytometry figures of cell-cycle arrest upon treatment of RG7388 and Nutlin-3a for 24 h (Figure S2); flow cytometry figures of apoptosis induction upon treatment of Nutlin-3a for 48 h (Figure S3); efficacy studies in the RKO xenograft model in nude mice (Figure S4); western blot analysis of 31 (YL93) and RG7388 in HCT-116 cells (Figure S5); cell growth inhibition of YL93, YM129, RG7388, and Nutlin-3 in HEK-293 cells (Figure S6); pharmacokinetic parameters of YL93 in ICR mice (Table S1); and X-ray crystallography data of 57 (Table S2) (PDF)Molecular formula string (CSV)This article has not yet been cited by other publications.

In Vitro Cytotoxicity and in Vivo Efficacy, Pharmacokinetics, and Metabolism of Pyrazole-Based Small Molecule Inhibitors of Mdm2/4–p53 Interaction

Small Molecule Inhibitors of the P53-Mdm2

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives As Novel Inhibitors of P53-Mdm2 Protein-Protein Interaction.

Pharmacological Activation of the P53 Pathway by a New Compound CYZ2017 Exerts Anti-Tumor Effects

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Design, Synthesis and Structure–activity Relationship of 4,5-Dihydropyrrolo[3,4-c]pyrazol-6(1h)-ones As Potent P53-Mdm2 Inhibitors

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

Patented Small Molecule Inhibitors of P53–mdm2 Interaction

Pharmacologic Activation of P53 by Small-Molecule MDM2 Antagonists.

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Computational Analysis of Spiro-Oxindole Inhibitors of the MDM2-p53 Interaction: Insights and Selection of Novel Inhibitors.

Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells

Recent Advances of P53-Mdm2 Small Molecule Inhibitors (2011-Present).

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.

Synthesis and Biological Evaluation of Novel Pyrimido[4,5-B]quinoline-2,4- Dione Derivatives As MDM2 Ubiquitin Ligase Inhibitors.

The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy